Clinical Trials Logo

Cardiac Amyloidosis clinical trials

View clinical trials related to Cardiac Amyloidosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03119558 Completed - Cardiac Amyloidosis Clinical Trials

PET/MRI Evaluation of Cardiac Amyloid

Start date: May 26, 2016
Phase: Early Phase 1
Study type: Interventional

Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F‑Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

NCT ID: NCT01623245 Completed - Cardiac Amyloidosis Clinical Trials

Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy

Amylo
Start date: June 2012
Phase:
Study type: Observational

Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture. Amyloidosis in transthyretin (TTR) are the most common hereditary amyloidosis but remain poorly studied at heart. This is serious and deadly. The prevalence of TTR amyloidosis is probably underestimated in hypertrophic cardiomyopathy (HCM) often of unknown etiology because of the lack of systematic implementation of myocardial biopsy because of their side effects.